Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 0: clinchem.2005.058560v1, 2005; 10.1373/clinchem.2005.058560
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2005.058560v1
52/2/171    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bossuyt, X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bossuyt, X.

Received on July 31, 2005
Accepted on November 18, 2005

Review

Serologic Markers in Inflammatory Bowel Disease

Xavier Bossuyt 1*

1 Laboratory Medicine, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium

* To whom correspondence should be addressed. E-mail: Xavier.Bossuyt{at}uz.kuleuven.ac.be.

Inflammatory bowel disease (IBD) is an enduring disease involving mostly young people, with symptoms of bloody diarrhea and abdominal cramps. Several antibodies have been associated with IBD, the 2 most comprehensively studied being autoantibodies to neutrophils (atypical perinuclear anti-neutrophil cytoplasmic antibodies) and anti-Saccharomyces cerevisiae antibodies. This review focuses on the value of these antibodies for diagnosing IBD, differentiating Crohn disease from ulcerative colitis, indeterminate colitis, monitoring disease, defining clinical phenotypes, predicting response to therapy, and as subclinical markers. Pancreatic antibodies and newly identified anti-microbial antibodies (anti-outer membrane porin C, anti-I2, and anti-flagellin) are also reviewed.


The following articles in journals at HighWire Press have cited this article:


Home page
 Mol. Cell. ProteomicsHome page
C.-S. Chen, S. Sullivan, T. Anderson, A. C. Tan, P. J. Alex, S. R. Brant, C. Cuffari, T. M. Bayless, M. V. Talor, C. L. Burek, et al.
Identification of Novel Serological Biomarkers for Inflammatory Bowel Disease Using Escherichia coli Proteome Chip
Mol. Cell. Proteomics, August 1, 2009; 8(8): 1765 - 1776.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
M. Papp, I. Altorjay, G. Lakos, J. Tumpek, S. Sipka, T. Dinya, K. Palatka, G. Veres, M. Udvardy, and P. L. Lakatos
Evaluation of the Combined Application of Ethanol-Fixed and Formaldehyde-Fixed Neutrophil Substrates for Identifying Atypical Perinuclear Antineutrophil Cytoplasmic Antibodies in Inflammatory Bowel Disease
Clin. Vaccine Immunol., April 1, 2009; 16(4): 464 - 470.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
N. Vermeulen, I. Arijs, S. Joossens, S. Vermeire, S. Clerens, K. Van den Bergh, G. Michiels, L. Arckens, F. Schuit, L. Van Lommel, et al.
Anti-{alpha}-enolase Antibodies in Patients with Inflammatory Bowel Disease
Clin. Chem., March 1, 2008; 54(3): 534 - 541.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
L. Henckaerts, M. Pierik, M. Joossens, M. Ferrante, P. Rutgeerts, and S. Vermeire
Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease
Gut, November 1, 2007; 56(11): 1536 - 1542.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
M. Ferrante, L. Henckaerts, M. Joossens, M. Pierik, S. Joossens, N. Dotan, G. L Norman, R. T Altstock, K. Van Steen, P. Rutgeerts, et al.
New serological markers in inflammatory bowel disease are associated with complicated disease behaviour
Gut, October 1, 2007; 56(10): 1394 - 1403.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2005 by the American Association for Clinical Chemistry.